Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Dr. Geoffrey S. Ginsburg joins VisEn Medical's scientific advisory board

Abstract:
Heritage in Genomic Profiling and Molecular Medicine Tightly Linked with VisEn's Molecular Imaging Technology Platforms and Development Programs

VisEn Medical, Inc., a leader in fluorescence in vivo imaging of biologic and molecular activities from research through medicine, today announced that Geoffrey S. Ginsburg, M.D., Ph.D. has joined its Scientific Advisory Board.

Dr. Geoffrey S. Ginsburg joins VisEn Medical's scientific advisory board

Woburn, MA | Posted on December 8th, 2006

Dr. Ginsburg is Professor of Medicine and Pathology and Director of the Center for Genomic Medicine at Duke University's Institute for Genome Sciences & Policy. Dr. Ginsburg's work centers on the identification and application of predictive biomarkers in developing and applying novel therapies and for improved research and clinical medicine.

VisEn's fluorescence imaging technologies provide the industry's most robust imaging performance in identifying, characterizing and quantifying a range of biomarkers in vivo, including known molecular activities underlying disease states such as cancer, inflammation, cardiovascular and bone disease. By imaging these disease-related biological activities in vivo, VisEn's technology platforms enable expanded areas of research, more efficient drug development, and truly tailored clinical medicine into the future.

Kirtland G. Poss, President and Chief Executive Officer of VisEn commented on the announcement, "Dr. Ginsburg's deep heritage and expertise in genomics, biomarkers, pharmaceutical development and personalized medicine builds directly into VisEn's mission of developing and applying fluorescence imaging technologies from in vivo research through clinical medicine. We are honored by his participation with VisEn and see this as yet another key foundation for our company's leadership in clinically directed molecular imaging."

Dr. Ginsburg stated, "The future of clinical medicine will be built around linked understandings, readouts and treatments of disease-related biomarkers in patient populations. VisEn's real-time in vivo imaging of biologic and molecular processes is playing an increasingly central role in basic research and drug development today, and there is a close parallel between these approaches and the advanced molecular profiling work being carried out at our center."

"By bringing together the industry experts and leaders in the fields of genomics, biomarkers, imaging and therapeutic intervention, we will work to produce new approaches to pharmaceutical development and personalized medicine that will have a truly positive impact on healthcare delivery," added Dr. Ginsburg. "I look forward to collaborating even more deeply with VisEn's
leading Scientific Advisory Board to further advance this promising new area of medicine."

Prior to his academic career, Dr. Ginsburg was Director of Cardiovascular Disease and Vice President of Molecular and Personalized Medicine at Millennium Pharmaceuticals. In these roles, he was responsible for Millennium's personalized medicine initiatives to develop biomarkers for disease
and pharmacogenomic strategies for therapeutics and their implementation in the drug development process. His responsibilities also included translational research efforts and strategic academic alliances required to integrate genomics into the practice of medicine.

####

About VisEn Medical, Inc.
VisEn Medical, Inc. was founded in 2000 based on fluorescence imaging technologies initially developed at the Massachusetts General Hospital and
Harvard Medical School. VisEn is developing today's highest performing
fluorescence molecular imaging technology platforms, from research through
medicine. VisEn also works directly with its partners to design ranges of
tailored probes and applications that are targeted to their specific research
areas. Privately-held VisEn is headquartered in Woburn, Massachusetts and
has been financed by leading venture firms including Flagship Ventures and
The Bollard Group. For further information please visit http://www.visenmedical.com.

For more information, please click here

Contacts:
Bryan Murphy
LaVoie Group
978.745.4200 x105

Copyright © VisEn Medical, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Announcements

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016

Construction of practical quantum computers radically simplified: Scientists invent ground-breaking new method that puts quantum computers within reach December 5th, 2016

Tools

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Controlled electron pulses November 30th, 2016

Scientists shrink electron gun to matchbox size: Terahertz technology has the potential to enable new applications November 25th, 2016

News from Quorum: The Agricultural Research Service of the USDA uses a Quorum Cryo-SEM preparation system for the study of mites, ticks and other soft bodied organisms November 22nd, 2016

Appointments/Promotions/New hires/Resignations/Deaths

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

Dr Barbara Armbruster joins XEI Scientific as Marketing Director June 1st, 2016

Park Systems Global Expansion in AFM Market Includes Appointment of New Executives April 23rd, 2016

GLOBALFOUNDRIES Adds Alain Mutricy as Head of Product Management Group March 3rd, 2016

Human Interest/Art

Weizmann Institute of Science Presents: Weizmann Wonder Wander - 4G - is Online June 21st, 2016

Call for NanoArt and Art-Science-Technology Papers June 9th, 2016

Scientists propose non-animal tools for assessing the toxicity of nanomaterials: Particle and Fibre Toxicology publishes recommendations from expert group meeting April 26th, 2016

Are humans the new supercomputer?Today, people of all backgrounds can contribute to solving serious scientific problems by playing computer games. A Danish research group has extended the limits of quantum physics calculations and simultaneously blurred the boundaries between mac April 14th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project